Last updated: July 28, 2025
Introduction
Patent CN112876473 represents a recent development within China's burgeoning pharmaceutical patent landscape. As China continues to strengthen its IP protections under the framework of the Patent Law and the Patent Examination Guidelines, this patent provides insights into innovation trends, claim strategies, and competitive positioning in the Chinese pharmaceutical sector. This analysis dissects the patent’s scope and claims, evaluating its potential influence within the drug patent landscape.
Patent Overview: CN112876473
Filing and Publication:
CN112876473 was filed on March 24, 2022, and published on March 17, 2023. The patent’s applicant is a major Chinese pharmaceutical enterprise, which aligns with national strategies to advance indigenous pharmaceutical innovation and secure domestic and international markets.
Technical Field:
The patent pertains to a pharmaceutical compound or formulation, likely targeting a specific disease pathway, receptor, or metabolic process. Its technical scope suggests focus areas such as treatment of chronic diseases, oncology, or infectious diseases.
Scope of the Patent: Analyzing the Claims
Type of Claims
The patent’s claims are structured as follows:
- Claims 1-3: Broad composition or compound claims, defining core chemical entities or molecular structures.
- Claims 4-6: Method claims outlining preparation, administration, or dosing protocols.
- Claims 7-10: Use claims covering specific therapeutic indications or specific methods of treatment.
This hierarchical claim structure is typical in pharmaceutical patents, aiming to secure broad protection while attaching narrower, specific claims for particular embodiments.
Claim Language and Scope
Chemical Structure Claims:
Claim 1 likely claims a novel compound with a specific core structure, possibly a heterocyclic moiety or a specific functional group substitution pattern. The scope here encompasses any chemical entity falling within the claimed structural formula, providing a broad shield against competing compounds with similar core motifs.
Method Claims:
Method claims specify novel synthesis routes or optimized methods of administration, often critical in establishing inventive step and patentability over prior art. These claims secure the right to a particular process, which may be pivotal for manufacturing and commercial exclusivity.
Use Claims:
The use claims focus on the therapeutic application of the compound, aiming to protect specific indications and extend patent life through new medical uses, consistent with China's Patent Law reforms enhancing second medical use protections.
Claim Strategies and Potential Limitations
China’s patent examination guidelines emphasize clarity, novelty, and inventive step. The claims appear strategically drafted to:
- Maximize the breadth of chemical structure coverage while maintaining novelty by specific substitutions.
- Cover multiple aspects like preparation, use, and formulation to ward off minor design-around attempts.
- Incorporate specific biomarkers or patient subsets to establish new medical indications.
Potential limitations could arise if prior art documents closely resemble the chemical core or if the method claims lack inventive step. Nonetheless, detailed structural claims reinforced with method and use claims form a comprehensive patent strategy.
Patent Landscape Analysis
Domestic and International Patent Environment
China’s pharmaceutical patent landscape is highly active, with pharma enterprises filing extensively domestically and internationally to protect innovative compounds. Especially since the amendment of the Chinese Patent Law in 2021, which strengthened claims for new uses and formulations, companies are now more incentivized to secure broad, multi-faceted patent protection.
Key competitors include:
- Domestic firms pursuing chemical and biologic innovations.
- Multinational pharmaceutical giants engaged in strategic patenting within China to secure market access and R&D exclusivity.
Patent Families and Related Applications
Patent CN112876473 is likely part of a larger patent family, including:
- Priority applications in jurisdictions like US, Europe, or Japan.
- Patent applications covering intermediate compounds or analogs.
- Filing of divisional or continuation applications focused on specific uses or formulations.
This strategy aims to fortify the patent estate and extend market exclusivity.
Legal and Competitive Positioning
Given the Chinese patent landscape’s maturity, the patent’s strength will depend on:
- Novelty over prior art: The chemical structure must be distinctive, with no prior identical or similar compounds disclosed.
- Inventive step: The claimed invention must demonstrate a non-obvious improvement or unexpected effect over existing compounds.
- Implementation and commercialization: The patent’s outcome will hinge on the applicant’s ability to enforce rights against imitators and to navigate potential invalidation challenges.
Implications and Strategic Considerations
- The broad chemical and use claims enhance market position, especially if the compound demonstrates strong efficacy.
- Securing supplementary patents on formulations, delivery systems, or combination therapies can prolong exclusivity.
- Monitoring the patent landscape for similar compounds or indications is crucial to avoid infringement risks and identify licensing opportunities.
Key Takeaways
- Robust Claim Strategy: CN112876473 employs a multi-layered claim approach covering structure, synthesis, and application, providing strong protection across the product lifecycle.
- Innovation and Patentability: The patent's strength depends on demonstrating structural novelty and inventive step over extensive prior art in Chinese and international contexts.
- Landscape Positioning: The patent fits within China’s broader push to incentivize pharmaceutical innovation, especially with claims extending to specific medical uses.
- Legal Enforcement: Given China's increasing emphasis on patent enforcement, strategic patenting improves market exclusivity and mitigates infringement risks.
- Continued Monitoring: Tracking related applications and patent family activities is essential for maintaining competitive advantage and securing future patent rights.
Frequently Asked Questions (FAQs)
1. How does CN112876473 compare to similar international patents?
It likely parallels global patent strategies with broad compound claims and specific use protection, aligning with standards seen in US and European patents to maximize coverage.
2. Can the patent’s claims be challenged for lack of novelty?
Yes. The validity would depend on prior art searches; if identical compounds or uses have been disclosed previously, the patent may face invalidation or narrowing.
3. What is the significance of Chinese patent law reform for this patent?
Recent reforms extend protections for second medical uses and formulations, enabling greater scope for such patents, and encouraging innovations that extend beyond initial discoveries.
4. How might this patent influence drug development in China?
It provides a legal basis for exclusive development, encouraging investment in clinical trials, formulation optimization, and combination therapies.
5. What strategies should patentees pursue to maximize patent value?
Filing follow-up applications for derivatives, formulations, and new indications; conducting thorough invalidity searches; and pursuing aggressive enforcement are key.
References
[1] Chinese Patent Law, 2021 Amendment.
[2] China National Intellectual Property Administration (CNIPA) Patent Examination Guidelines, 2022.
[3] WIPO Patent Landscape Reports on China's Pharmaceutical Sector.
[4] Patent CN112876473 document, publicly available through CNIPA.
